|
VFA (cm2)
|
<100
|
≥100
|
p value*
|
|---|
|
SFA (cm2)
|
<100 (N = 34)
|
≥100 (N = 39)
|
<100 (N = 11)
|
≥100 (N = 34)
|
|---|
|
OHA (%)
|
41.2
|
33.3
|
54.5
|
54.7
|
0.164
|
|
Sulfonylureas (%)
|
25.0
|
0.0
|
12.5
|
22.4
|
0.055
|
|
Biguanides (%)
|
16.7
|
15.4
|
0.0
|
40.8
|
0.012
|
|
Alpha-GIs (%)
|
25.0
|
0.0
|
12.5
|
10.2
|
0.048
|
|
TZDs (%)
|
8.3
|
0.0
|
7.7
|
6.1
|
0.301
|
|
DPP4 inhibitors (%)
|
25.0
|
42.3
|
62.5
|
34.7
|
0.245
|
|
Glinides (%)
|
8.3
|
0.0
|
0.0
|
0.0
|
0.070
|
|
GLP-1 agonists (%)
|
0.0
|
0.0
|
0.0
|
2.0
|
0.754
|
|
Insulin (%)
|
41.2
|
38.5
|
18.2
|
35.9
|
0.575
|
|
ACEIs (%)
|
0.0
|
5.4
|
0.0
|
3.2
|
0.516
|
|
ARBs (%)
|
17.6
|
24.3
|
45.5
|
44.4
|
0.025
|
|
CCBs (%)
|
11.8
|
5.4
|
36.4
|
30.2
|
0.007
|
|
Beta blockers (%)
|
5.9
|
18.9
|
18.2
|
14.3
|
0.424
|
|
Alpha blockers (%)
|
0.0
|
5.4
|
0.0
|
1.6
|
0.383
|
|
Diuretics (%)
|
5.9
|
24.3
|
9.1
|
11.1
|
0.110
|
|
Statins (%)
|
11.8
|
16.2
|
0.0
|
34.9
|
0.007
|
|
Fibrates (%)
|
0.0
|
0.0
|
0.0
|
3.2
|
0.451
|
|
UA-lowering agents
|
0.0
|
10.8
|
9.1
|
6.3
|
0.289
|
|
Anti-platelets (%)
|
11.8
|
0.0
|
9.1
|
12.7
|
0.168
|
- Data are expressed as percentage
-
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, DPP4 dipeptidyl peptidase-4, GI glycosidase inhibitor, GLP-1 glucagon-like peptide-1, OHA oral hypoglycemic agent, TZD thiazolidinedione, UA uric acid
- * Chi square test
